SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 11th, 2023 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 9, 2023, is by and among PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 11th, 2023 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances)
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 9, 2023, is by and among PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
KATALYST SECURITIES LLCPharmaCyte Biotech, Inc. • May 11th, 2023 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, as exclusive placement agent (the “Placement Agent”), by Pharmacyte Biotech, Inc., a publicly traded Nevada corporation (the “Company”), to assist the Company in connection with the private placement financing of Securities (as defined below) (the “Offering”) for the Company on an exclusive basis. The Offering will be made pursuant to the exemptions afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and applicable state securities laws. The terms and conditions of the Offering are further defined in the Confidential and Non-Binding Summary Term Sheet attached as Exhibit A hereto and dated herewith, which terms and conditions to the extent not in conflict with the terms and conditions
